Clinical Trials
20 trialsNCT07255963 2025-12-01
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT02790515 2025-08-12
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT07034508 2025-06-24
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT02531308 2022-09-28
DLBCL
Rush University Medical Center
Phase 2 Terminated
NCT00003716 2022-05-31
Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy
Stanford University
Phase 2 Completed
NCT00553943 2018-08-23
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Lymphoma Study Association
Phase 2 Completed
NCT00867529 2018-01-02
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00617929 2017-12-28
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00983944 2017-11-30
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02259348 2017-05-30
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01282476 2017-05-09
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT00324779 2015-09-25
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00057811 2014-09-19
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00058461 2013-10-08
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00799136 2013-09-12
CATCH
Ontario Clinical Oncology Group (OCOG)
Phase 2 Completed
NCT01118845 2013-07-04
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
SymBio Pharmaceuticals
Phase 2 Completed
NCT00980304 2009-09-21
R Retreatment in 1st Relapsed DLBCL
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT00127569 2007-01-12
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
French National Agency for Research on AIDS and Viral Hepatitis
Phase 2 Terminated